Rare Disease Report

VBP15 - A new and improved Glucocorticoid for Treating Duchenne

APRIL 30, 2015

The orphan drug VBP15 being developed by Reveragen biopharma for Duchenne muscular dystrophy is a new first-in-human steroidal drug that effectively separates a number of subactivities seen in traditional glucocorticoid drugs.

In this interview with Eric Hoffman, PhD, president and chief executive officer of Reveragen, he describes the4 subactivities in detail that should make VBP15 a more suitable glucocorticoid for treating boys with Duchenne muscular dystrophy.

For more information, click here.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.